首页> 美国卫生研究院文献>Cancers >Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review
【2h】

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review

机译:循环肿瘤DNA在胰腺导管腺癌中的数码液滴PCR检测:系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pancreatic cancer is a digestive tumor that is most difficult to treat and carries one of the worst prognoses. The anatomical location of the pancreas makes it very difficult to obtain enough tumor material to establish a molecular diagnosis, so knowing the biology of this tumor and implementing new targeted-therapies is still a pending issue. The use of liquid biopsy, a blood sample test to detect circulating-tumor DNA fragments (ctDNA), is key to overcoming this difficulty and improving the evolution of this tumor. Liquid biopsies are equally representative of the tissue from which they come and allow relevant molecular and diagnostic information to be obtained in a faster and less invasive way. One challenge related to ctDNA is the lack of consistency in the study design. Moreover, ctDNA accounts for only a small percentage of the total cell-free circulating DNA and prior knowledge about particular mutations is usually required. Thus, our aim was to understand the current role and future perspectives of ctDNA in pancreatic cancer using digital-droplet PCR technology.
机译:胰腺癌是一种消化肿瘤,最难以治疗和携带最糟糕的预期之一。胰腺的解剖学位置使得获得足够的肿瘤材料来建立分子诊断非常困难,因此了解这种肿瘤的生物学并实施新的靶向治疗仍然是一个待决的问题。使用液体活检,血液样品测试检测循环肿瘤DNA片段(CTDNA),是克服这种困难和改善这种肿瘤的演变的关键。液体活组织检查同样代表它们来自的组织,并允许以更快和更少的侵入方式获得相关的分子和诊断信息。与CTDNA相关的一个挑战是研究设计中缺乏一致性。此外,CTDNA仅占总细胞无细胞循环DNA的小百分比,并且通常需要关于特定突变的先验知识。因此,我们的目的是了解使用数字液滴PCR技术了解CTDNA在胰腺癌中的目前的作用和未来观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号